linjc16/ctgov huggingface dataset:
The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate the effect of metformin on the correlation between hyperinsulinemia and hypertension.

Official Title
-----------------
The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension

Conditions
-----------------
Diabetes Mellitus, Essential Hypertension

Intervention / Treatment
-----------------
* Drug: Fosinopril
* Drug: Metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 to 65 years of age, regardless of sex duration of hypertension was <5 years overweight or obesity, mild to moderate hypertension, receive no euglycemic agent or antiobesity drug

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fosinopril group<br>Fosinopril group received fosinopril, 10mg, once per day. | Drug: Fosinopril<br>* Fosinopril group received fosinopril, 10mg, once per day.<br>|
| Experimental: Metformin group<br>Metformin group was treated with metformin hydrochloride, 500mg, three times per day | Drug: Metformin<br>* Metformin group was treated with metformin hydrochloride, 500mg, three times per day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure measurement |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Insulin Resistance, Hyperinsulinemia, Metformin, Fosinopril
Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET

Study Overview
=================
Brief Summary
-----------------
Observe the clinical efficacy and safety of Recombinant Human Growth Hormone Injection assisted in the treatment of the patients with poor ovarian response in vitro fertilization and embryo transfer.

Official Title
-----------------
Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of Poor Ovarian Response (POR) Clinical Outcome in Patients Undergoing in Vitro Fertilization / Embryo Transfer (IVF/ET)

Conditions
-----------------
Poor Ovarian Response

Intervention / Treatment
-----------------
* Procedure: Conventional ovarian stimulation proctol without rhGH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, age 30-42 years old. Diagnosis of POR (2011 ESHRE Bologna Standard). At least two previous IVF failure history. Voluntarily to sign the informed consent. Exclusion Criteria: Severe acute and chronic liver and kidney disease，Such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity period, etc.；Liver and kidney dysfunction. Endocrine and metabolic diseases，eg, diabetes、Thyroid function hyperthyroidism, Thyroid dysfunction, cushing's syndrome, hyperprolactinemia，hyperandrogenism. Related diseases affecting outcome of IVF pregnancy，eg, hydrosalpinx, hysteromyoma≥4cm, adenomyosis, stage III and IV endometriosis, untreated endometrial lesions, uterine malformation, genital tuberculosis, malignant tumor of reproductive system （include endometrial carcinoma, cervical carcinoma, ovarian cancer, fallopian tube carcinoma）. Allergic to E. coli expression product and its excipients. Subjects who participated in the past three months or are participating in other drug clinical researchers. IVF failure history≥3. The researchers consider who is not suitable for enrolling the group.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GH AQ<br> | Procedure: Conventional ovarian stimulation proctol without rhGH<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate |  | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of retrieved oocytes |  | One year | 
| Number of high quality embryos |  | One year | 
| Number of embryos transferred |  | One year |
Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis

Study Overview
=================
Brief Summary
-----------------
This is a multicentre, randomised, double-masked, parallel-group, phase IV comparison of Posiformin 2 % eye ointment (active substance: bibrocathol) in the treatment of blepharitis.

Detailed Description
-----------------
Reduction of signs and symptoms of blepharitis

Official Title
-----------------
Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis - a Multi-centre, Randomised, Double-masked, Parallel-group, Phase IV Comparison

Conditions
-----------------
Blepharitis, Signs and Symptoms

Intervention / Treatment
-----------------
* Drug: Posiformin 2 %, bibrocathol
* Drug: Placebo Comparator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: written informed consent ambulatory male and female patients 18 years of age or older summarised score of signs and symptoms of blepharitis of 15 or more at baseline Exclusion Criteria: different ocular conditions different system conditions several concomitant medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Posiformin 2 %<br>Eye ointment applied to the eye lid | Drug: Posiformin 2 %, bibrocathol<br>* A strip of 5 mm eye ointment applied 3 times per day to the eye lid<br>|
| Placebo Comparator: Placebo<br>corresponding vehicle, eye ointment applied to the eye lid | Drug: Placebo Comparator<br>* corresponding vehicle, eye ointment applied to the eye lid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of Posiformin 2% in reduction of signs and symptoms of blepharitis | Changes from baseline in the sumscore which comprises lid edema, lid erythema, debris, pouting of Meibomian glands by slit lamp examination | 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in blepharitis signs and symptoms | Changes between baseline and end of treatment in lid edema, lid erythema, debris, pouting of meibomian glands, ocular discomfort, antiseptic effect | 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bibrocathol, eye ointment, blepharitis, eye lid
Portable Oxygen Concentrator Signal Capture Study

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to learn how patients breathe on portable oxygen concentrators (POCs), and to get feedback from patients using POCs.

Detailed Description
-----------------
This study aims to examine patient oxygenation levels and markers of exertion (e.g. breath rate, heart rate and breath pattern) while using a portable oxygen concentrator, with the aim to understand exercise desaturation in hypoxemic subjects.

Official Title
-----------------
Portable Oxygen Concentrator Signal Capture Study

Conditions
-----------------
Hypoxia

Intervention / Treatment
-----------------
* Device: Portable pulsed oxygen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is willing to give written informed consent Patient can read and comprehend English Patient is ≥ 18 years of age Patient has moderate to severe hypoxaemia (SpO2 ≤ 92%) at rest Patient reports shortness of breath on exertion Exclusion Criteria: Patient has musculoskeletal impairment, or other impairment that may be the limiting factor in 6MWT Patient has a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study Patient has acute coronary syndrome, acute myo- or pericarditis, acute lung embolism, pulmonary infarction, acute uncontrolled heart insufficiency Patient shows signs of acute exacerbation of underlying lung condition Patient is deemed to be unsuitable for inclusion in the opinion of the researcher, including for the following reasons: they do not comprehend English they are unable to provide written informed consent they are physically unable to comply with the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study group<br>Portable pulsed oxygen | Device: Portable pulsed oxygen<br>* Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxygenation | SpO2 during rest and exercise using portable pulsed oxygen therapy | 20 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart rate | Heart rate during rest and exercise using portable pulsed oxygen therapy | 20 minutes | 
| Nasal cannula pressure | Nasal cannula pressure during rest and exercise using portable pulsed oxygen therapy | 20 minutes |
Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis

Study Overview
=================
Brief Summary
-----------------
Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of the skin and all internal organs. Interstitial lung disease is a frequent morbidity and mortality-driving manifestation in systemic sclerosis. This observational trial (OT) is part of the collaborative project DeSScipher, one out of five OTs to decipher the optimal management of systemic sclerosis. Aim of this observational try is to identify: The state of clinical practice in Europe for prevention and treatment of interstitial lung disease and its impact on lung function and disease progression The potential predictors and confounders for response to therapy

Detailed Description
-----------------
Patients are routinely evaluated every 3 months over a 12-months period by medical history, physical examination, pulmonary function tests, VAS lung score and SF-36, SHAQ. Also, their medication and possible medication changes will be recorded.

Official Title
-----------------
Prevention and Treatment of Interstitial Lung Disease in Systemic Sclerosis

Conditions
-----------------
Systemic Sclerosis, Interstitial Lung Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis fo SSc according to the ACR/EULAR criteria for adult or the PRES/ACR/EULAR criteria for juvenile SSc patients SSc patients with proven ILD (by X-ray or CT scan) Treatment with standard dosages according to current practice with (i) cyclophosphamide, (ii) azathioprine, (iii) mycophenolate mofetil, (iv) methotrexate, or (v) no therapy Exclusion Criterion: Patients with previous exposure to silica or asbestos
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cyclophosphamide<br>Patients receiving cyclophosphamide | |
| azathioprine<br>Patients receiving azathioprine | |
| mycophenolate mofetil<br>Patients receiving mycophenolate mofetil | |
| methotrexate<br>Patients receiving methotrexate | |
| no therapy<br>Patients receiving no immunosuppressive therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with 10% decline in FVC | The proportion of patients with ILD progression as defined by a 10% decline in FVC within 1 year of therapy | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The time to a 15% decline in DLCO or a drop <55% of predicted lung function |  | 1 year | 
| The mortality due to lung fibrosis |  | 1 year | 
| The need for oxygen support |  | 1 year |
Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence

Study Overview
=================
Brief Summary
-----------------
Major hepatectomies are generally selected for tumors involving the hepatic vein (HV) at the caval confluence (CC). As alternative, HV reconstruction has been proposed. The present study aimed to evaluate the feasibility and safety of a HV-sparing policy guided by intraoperative ultrasonography (IOUS) in a cohort of patients having at least one colorectal liver metastasis (CLM) in contact with a HV at CC. HV section can be avoided in the large majority of cases thanking to CLMs detachment or to HV partial resection or reconstruction: this policy seems feasible, safe, reduces the need of major hepatectomies, and oncologically provides an adequate local control.

Official Title
-----------------
Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence: Validation on Intention-to-treat Analysis of a IOUS-guided Approach

Conditions
-----------------
Secondary Malignant Neoplasm of Liver

Intervention / Treatment
-----------------
* Procedure: Hepatic vein-sparing hepatectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of at least one CLM in contact with HV at caval confluence and HV patency at preoperative imaging at least 6 months of follow-up after surgery Exclusion Criteria: suspected or ascertained thrombosis or full tumoral involvement of HV at preoperative imaging portal pedicle infiltration and/or thrombosis unresectability at laparotomy for any extra-hepatic or intrahepatic reason not related to tumor-vessel relations

Ages Eligible for Study
-----------------
Minimum Age: 28 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients having at least one CLM<br>Hepatic vein-sparing hepatectomy guided by intraoperative ultrasonography | Procedure: Hepatic vein-sparing hepatectomy<br>* HV detachment, partial resection and section on the basis of HV-CLM relationship<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the safety of HV-sparing surgery in terms of operative mortality and morbidity |  | within 30-90 days after surgery |
Lag of Accommodation With DOT Spectacle Lenses

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to measure the difference in the lag of accommodation between DOT spectacle lenses and control spectacles.

Official Title
-----------------
Lag of Accommodation With DOT Spectacle Lenses

Conditions
-----------------
Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast

Intervention / Treatment
-----------------
* Device: DOT Pattern
* Device: Control Spectacles


Participation Criteria
=================
Eligibility Criteria
-----------------
A person is eligible for inclusion in the study if he/she: Age 6-18 years of age, with a maximum of 6 of the first 25 completed participants being older than 14 years of age. Is able to read (or be read to), understand and sign the assent document if under 17 years old or is able to read, understand and sign the consent document if aged 17 or 18 years. Is under 17 years old and is accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document. Should be emmetropic by non-cycloplegic auto-refraction, which means both refractive meridians should be within +1.00D and -1.00D. Is willing and able to follow instructions. A person will be excluded from the study if he/she: Is participating in any concurrent clinical or research study. Have a history of myopia control treatment in the past year. Has amblyopia in either eye or known to have any other binocular vision disorder, such as accommodative insufficiency. Has any known active ocular disease and/or infection. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable. Examples include diabetes mellitus, hyperthyroidism. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable. Examples include Atropine eye drops. Has undergone strabismus surgery, refractive error surgery or intraocular surgery. Is a child of a member of the study team.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment 1 - DOT Pattern<br>Spectacle lens or treatment 1 | Device: DOT Pattern<br>* DOT Pattern Spectacle Lens<br>|
| Active Comparator: Treatment 2 - Control Spectacles<br>Comparator lens or control arm | Device: Control Spectacles<br>* Control lens<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best vision sphere | 1) Autorefractor spherical equivalent refraction measured at distance and at 40cm with each pair of treatment spectacles | 90 minutes |
Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System

Study Overview
=================
Brief Summary
-----------------
Prospective, multi-center clinical study to evaluate the clinical outcomes of the posterior stabilized design of the LCS® Complete Mobile-bearing Total Knee System

Detailed Description
-----------------
Prospective, multi-center study to evaluate the clinical outcome of posterior stabilized design of LCS® Complete Mobile-Bearing Total Knee System. No comparison group. 12 month enrollment, 12 month post-operative evaluation. Follow-up intervals: Pre-op, 3 month, 6 month, and 12 month.

Official Title
-----------------
LCS® PS: A Prospective, Multi-center Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System

Conditions
-----------------
Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Juvenile Arthritis

Intervention / Treatment
-----------------
* Device: Total knee arthroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: M/F 18-80 Diagnosis of osteoarthritis, rheumatoid , post-traumatic, inflammatory, juvenile arthritis. Skeletally mature, sufficient bone stock to seat and support prosthesis Willing/able return for follow-up. Subject is willing and able to provide informed patient consent for participation in the study Exclusion Criteria: History of recent/active joint sepsis, charcot neuropathy, psycho-social disorders, prior knee arthroplasty on affected site, metabolic disorders of calcified tissue Communicable diseases that may limit follow-up Medical-legal or workers compensation claims.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: LCS Complete Posterior Stabilized knee implant<br>Total knee arthroplasty with a posterior stabilized implant | Device: Total knee arthroplasty<br>* Total knee arthroplasty using a posterior stabilized implant<br>* Other names: LCS® Complete Posterior Stabilized Mobile-bearing Knee;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee Active Flexion | Active flexion is measured by how much a patient can bend their knee on their own, without assistance. | 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Total knee replacement, Total knee arthroplasty, Osteoarthritis, Rheumatoid or other inflammatory arthritis, Post-traumatic or juvenile arthritis